H
Hua Ma
Publications - 6
Citations - 933
Hua Ma is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 107 citations.
Papers
More filters
Journal ArticleDOI
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David K. C. Cooper,Timothy Jennings,Donald M Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: The vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of.
Journal ArticleDOI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Emmanuel B. Walter,Kawsar R. Talaat,Charu Sabharwal,Alejandra Gurtman,Stephen Lockhart,Grant Paulsen,Elizabeth D. Barnett,Flor M. Munoz,Yvonne Maldonado,Barbara A. Pahud,Joseph B. Domachowske,Eric A. F. Simões,Uzma N. Sarwar,Nicholas Kitchin,Luke Cunliffe,Pablo Rojo,Ernest Kuchar,Mika Rämet,Iona Munjal,John L. Perez,Robert W. Frenck,Eleni Lagkadinou,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Susan Mather,Todd Belanger,David K. C. Cooper,Özlem Türeci,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +33 more
TL;DR: A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age.
Journal ArticleDOI
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Flor M. Munoz,Lawrence Sher,Charu Sabharwal,Alejandra Gurtman,Xia Xu,Nicholas Kitchin,Stephen Lockhart,Robert Riesenberg,Joanna M Sexter,Hanna Czajka,Grant Paulsen,Yvonne Maldonado,Emmanuel B. Walter,Kawsar R. Talaat,Janet A. Englund,Uzma N. Sarwar,Caitlin Hansen,Martha Iwamoto,Chris Webber,Luke Cunliffe,Benita Ukkonen,Silvina N Martínez,Barbara A. Pahud,Iona Munjal,Joseph B. Domachowske,Kena A. Swanson,Hua Ma,Kenneth Koury,Susan Mather,Claire M. Lu,Jing Zou,Xuping Xie,Pei Yong Shi,David A. Cooper,Özlem Türeci,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +37 more
TL;DR: A phase 1 dose-finding study and an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age was conducted in this article .
Journal ArticleDOI
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David A. Cooper,Timothy W Jennings,Donald Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: In this paper , the BNT162b2 COVID-19 vaccine was used to prevent SARS-CoV-2 infections in participants who received the vaccine compared to those who did not.
Journal ArticleDOI
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
Eric A. F. Simões,Nicola P. Klein,Charu Sabharwal,Alejandra Gurtman,Nicholas Kitchin,Benita Ukkonen,Piotr Korbal,Jing Zou,Xuping Xie,Uzma N. Sarwar,Xia Xu,Stephen Lockhart,Luke Cunliffe,Claire M. Lu,Hua Ma,Kena A. Swanson,Kenneth Koury,Pei Yong Shi,David A. Cooper,Ӧzlem Türeci,Kathrin U. Jansen,Ugur Sahin,William C. Gruber +22 more
TL;DR: In this article , substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds.